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Abstract The occurrence of vitiligo in patients with
melanoma is especially reported for patients undergoing
immunotherapy. While vitiligo in these patients is thought
to be related to an immune response directed against mela-
noma cells, solid evidence is lacking. Here we report local
cytotoxic T cell reactivity in three melanoma patients
who developed vitiligo, after experimental immunotherapy
using dendritic cell vaccinations. Tetramer analysis showed
that vaccine-induced T cells recognizing gp100 and tyrosi-
nase are present at the vitiligo lesions. These T cells secrete
IFN- and IL-2 upon peptide speciWc stimulation as well as
upon recognition of the autologous tumor. We show that
functional CD8+ T cells speciWc for melanoma diVerentia-
tion antigens used in a melanoma immunotherapy trial, do
not only invade the tumor, but also the vitiligo lesions. This
directly links vitiligo to the immuno-therapeutic interven-
tion and supports the hypothesis that vitiligo is a marker of
immunity against melanoma cells.
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Abbreviations
CTL Cytotoxic T lymphocyte
MDA Melanoma diVerentiation antigen
DC Dendritic cell
VIL Vitiligo inWltrating lymphocyte
TIL Tumor inWltrating lymphocyte
Introduction
Vitiligo is a common skin disease that is characterized by
depigmented lesions associated with local destruction of
melanocytes [12]. For melanoma patients the chance to
develop vitiligo is estimated to be seven to tenfold higher
compared to the general population [22], especially when
they participate in an immunotherapeutic trial [25]. Based
on numerous observations, development of de novo vitiligo
lesions in melanoma patients is generally regarded as a
favourable prognostic factor.
The etiology of vitiligo is not yet completely understood,
but several lines of evidence suggest that both spontaneous
and immunotherapy-associated vitiligo are immune-mediated
processes. In spontaneous vitiligo, circulating anti-melanocytic
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progressive lesions are present [9, 17]. Furthermore, spon-
taneous vitiligo is correlated with circulating cytotoxic T
lymphocytes (CTLs) speciWc for melanoma diVerentiation
antigens (MDAs) [19]. Analysis of vitiligo inWltrating lym-
phocytes (VILs) isolated from vitiligo lesions showed a
local enrichment of predominantly Melan-A speciWc T cells
[11, 16, 30].
Numerous melanoma antigens are shared by normal
melanocytes; amongst these are MDAs such as Melan-A/
MART-1, gp100, tyrosinase and tyrosinase related proteins
[3, 7]. In two murine melanoma models, it is shown that
de novo development of vitiligo is associated with reduced
tumor progression. In both models, MDA-speciWc CTLs
play a crucial role in both tumor control and melanoma-
associated vitiligo [13, 18]. Also in humans the appearance
of vitiligo during the course of melanoma is thought to be
caused by a cross-reactive immune response directed
against melanoma cells, which explains the better prognosis
in these patients reported in literature [4, 29].
Here we describe three melanoma patients who devel-
oped vitiligo after immunotherapeutic intervention. Patients
were vaccinated with autologous monocyte-derived den-
dritic cells (DCs) loaded with gp100 and tyrosinase epi-
topes [5]. We demonstrate that CTLs against these epitopes
can be detected in low percentages in the peripheral blood
after vaccination. Interestingly, functional CTLs with the
same speciWcity were observed in high percentages in both
tumor and vitiligo lesions, which supports the hypothesis




Melanoma patients with regional lymph node and distant
metastases, participated in an experimental study using
autologous monocyte-derived DCs loaded with HLA-A2.1
compatible tumor antigens gp100 and tyrosinase [5]. Only
patients who developed vitiligo after immunotherapy, clini-
cally conWrmed by a dermatologist, were selected. Blood
samples and 6 mm biopsies of perilesional vitiligo were
obtained after informed consent. Approval from the local
regulatory committee was obtained.
Preparation of vitiligo-inWltrating lymphocytes (VILs)
Six mm punch biopsies of the perilesional vitiligo-site
(Fig. 1a) were obtained and cut in half. One part was cryo-
preserved for immunohistochemistry at a later timepoint,
Fig. 1 Vaccine-speciWc CTLs 
accumulate at the vitiligo lesion. 
Perilesional 6 mm skin biopsies 
were taken from each patient (a). 
CD-3 staining of the periolesion-
al skin showing lymphocyte 
inWltrates (b), original magniW-
cation £200. Flowcytometry of 
peripheral blood lymphocytes 
(PBLs, c) and vitiligo inWltrating 
lymphocytes (VILs, d) from one 
representative patient (patient 
3). From the scatterplot the lym-
phocytes were gated and double 
stained with anti-CD8-FITC and 
tetramer-PE. The numbers in the 
dot plots indicate the percentage 
of tetramer-reactive cells of the 
CD8+ cell fraction123
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by gentle squeezing in a sterile open Wlter chamber (NPBI,
Amsterdam, The Netherlands) in RPMI/7% human serum
(Sanquin, Nijmegen, The Netherlands) supplemented with
IL-2 (100 U/ml). The cell suspension was placed in a 24-
wells plate (Costar Badhoevedorp, The Netherlands). T
cells were morphologically and functionally tested after
2 weeks of culture.
Preparation of tumor-inWltrating lymphocytes (TILs) 
and melanoma cell lines
TILs were obtained and cultured according to the same pro-
tocol as the vitiligo cell suspension (see above). A tumor
cell line was generated by tumor culture in DMEM
(Gibco—Invitrogen) supplemented with 10% fetal calf
serum (Greiner). Fresh medium was added twice a week.
MHC Tetramer staining
VILs and TILs (50 £ 103 cells in 10 l) or 1 £ 106 periphe-
ral blood mononuclear cells in 10 l, were incubated with
directly labeled gp100154–162, gp100280–288, tryrosinase369–376
and Melan-A26–35 and HIV77–85 tetrameric-MHC-HLA-
A2.1 complexes for 60 min at room temperature. FITC-
conjugated monoclonal antibodies directed against CD8
(Becton Dickinson) were added during the last 20 min.
After washing, the samples were analyzed by Xow cytome-
try. Percentage tetramer positive cells were calculated over
the CD8+ fraction. All samples were tested with HIV77–85-
HLA-A2.1-tetramers recognizing the irrelevant HIV-pep-
tide SLYNTVATL as background control [5]. Control
tetramer binding was less than 0.02% in all samples
(supplementary Wgure 1).
Cytokine production
Production of cytokines by VILs and TILs were measured
in response to speciWc stimuli (target:eVector-ratio 1:1).
Two diVerent target cells were used: T2 cells pulsed with
gp100154–162, gp100280–288, tryrosinase369–376 or the irrele-
vant peptide HIV77–85 and BLM cells (a melanoma cell line
expressing HLA-A2.1 and no endogenous expression of
gp100 and tyrosinase) transfected with control antigen
G250, gp100 or tyrosinase. IFN- and IL-2 production were
measured in supernatants after 16 hours by cytometric bead
array according to the manufacturers protocol (Th1/Th2
Cytokine CBA 1; BD Pharmingen).
Antibodies and immunostaining
Regulatory T cell phenotype was assessed by Xowcytome-
try using mAbs directly conjugated to Xuorescent dyes. The
FOXP3-FITC (clone PCH101, eBioscience, San Diago,
CA, USA), CD4-APC, CD25-PE, CD127-PE-Cy5 (all
Becton Dickinson) were used according to manufacturers
protocols. Regulatory T cells were deWned as CD4+
FoxP3+CD25+CD127¡.
For immunohistochemistry, the following mAbs were
used: M2-7C10+M2-9E3 (Labvision, Fremont, CA, USA)
against Melan-A, SP7 (Labvision) against CD3, HMB-45
(Dako, Glostrup, Denmark) against gp100 and T311
(Novocastra, Newcastle, UK) against tyrosinase [6].
Results and discussion
Patients
We prospectively followed three HLA-A2.1 positive
patients with histologically documented melanoma who
received DC-based immunotherapy and subsequently
developed vitiligo (Table 1).
Patient 1. Patient 1 was diagnosed, two years prior to
inclusion, with melanoma of the scalp with regional lymph
node metastases (T3aN2aM0), for which a radical lymph
node dissection was performed. She relapsed with regional
lymph node and cutaneous metastases, which were resected
and treated with adjuvant radiotherapy. At inclusion, this
patient presented with multiple subcutaneous and lung
metastases. The patient was vaccinated intranodally with
antigen loaded mature DCs [5] but treatment was discontin-
ued after 3 vaccinations because of progression of cutane-
ous metastases. She developed vitiligo in the Xank during
further tumor progression.
Patient 2. Patient 2 was diagnosed, twelve years prior to
inclusion, with melanoma located on the right lower leg
(T1aN0M0), which was surgically removed. From 1997 on,
the patient relapsed with in transit and distant cutaneous
metastases, for which he was treated with regional limb
perfusion (melfalan) and dacarbazine. At inclusion, he was
diagnosed with lymph node metastases and multiple (sub-
)cutaneous metastases for which he was repeatedly vacci-
nated intranodally with antigen loaded mature DCs. After
three vaccinations, the patient developed vitiligo in the neck
region and dorsal side of both hands. To date, the vitiligo still
progresses and aVects the head, back, hands and legs.
Patient 3. Patient 3 was diagnosed, 6 months prior to
inclusion, with a superWcial spreading melanoma of the left
thigh (T1a/bN0M0). At inclusion she presented with an
inguinal lymph node metastasis, for which a radical lymph
node dissection was performed. She was vaccinated intra-
dermally in an adjuvant setting with antigen loaded mature
DCs. After eight vaccinations, she developed a severe rash
in the neck region, thorax, back and upper extremities and
subsequent vitiligo in these areas.123
























































































































































































































































































































































































































































































































































































































































Cancer Immunol Immunother (2009) 58:145–151 149Vitiligo development in melanoma patients upon vacci-
nation with DCs has been reported before [15, 24].
Although not investigated, it is currently believed that the
vitiligo in these patients results from sensitization to anti-
gens shared by melanocytes and melanoma cells. To
address this question we took perilesional biopsies and
studied the vitiligo inWltrating immune cells.
Vaccine speciWc lymphocytes inWltrate vitiligo lesions
Immunohistochemical analysis of the vitiligo in all three
patients demonstrates perilesional inWltration of T cells
(Fig. 1a, b). With tetramer analysis, CD8+ T cells speciWc
for one or more gp100 and tyrosinase HLA-A2.1 epitopes
were detected at low frequencies in the peripheral blood
after vaccination in all three patients. Gp100 or tyrosinase
speciWc CD8+ T cells were not detectable prior to vaccina-
tion (data not shown). Interestingly, speciWc CTLs were
detected at increased concentrations in the vitiligo lesion
compared to peripheral blood (Table 1; supplementary
Wgure 1). This phenomenon was most obvious in patient 3
(Fig. 1c, d). The accumulation of these CTLs in the vitiligo
lesions can result from speciWc migration [26] and/or a
local proliferation advantage for MDA speciWc CTLs
induced by perilesional antigen exposure.
Although the immunotherapy was not primarily directed
against the Melan-A epitope, Melan-A speciWc CTLs were
observed in the vitiligo lesions and tumor lesion of patient 1
and 2 (Table 1; Fig. 3). This Wnding is consistent with the
observation that anti-tumor vaccines can have eVects
beyond their intrinsic speciWcity. It is shown that the inter-
action of vaccine speciWc T cells with melanoma cells may
trigger a broad activation of other anti-tumor T cells, a phe-
nomenon called epitope spreading [10, 14].
Vitiligo inWltrating lymphocytes produce IFN- 
after speciWc stimulation
To test whether vitiligo inWltrating lymphocytes (VILs)
were functional, we stimulated these cells with gp100 or
tyrosinase expressing target cells and measured subsequent
IFN- and IL-2 production. VILs of patients 1 and 3 pro-
duce IFN- and IL-2 when exposed to gp100-target cells
and VILs of patient 2 produce IFN- and IL-2 when
exposed to both gp100 and tyrosinase-target cells. No cyto-
kines were produced when VILs were exposed to unloaded
control target cells (Fig. 2).
From patients 1 and 2 we were able to culture melanoma
cell lines from metastases. Interestingly, the VILs also pro-
duced IFN- and IL-2 when stimulated by the autologous
tumor cell line (Fig. 2). The cross reactivity of the VILs with
autologous tumor cells further supports the hypothesis that
the vitiligo is a marker of immunity against melanoma cells.
Vitiligo lesions in our patients did not speciWcally occur
at the vaccine injection-site, at the site of the primary
tumor, or in close proximity of new metastases. From this
we conclude that the melanoma-associated vitiligo is not
caused by a direct and local side-eVect of tumor destruc-
tion, but rather by the presence of circulating MDA-speciWc
CTLs. Although we did not use MHC class II peptides in
our vaccination protocol, our data do not exclude that spe-
ciWc CD4+ cells are involved. MDA-speciWc epitopes rec-
ognized by CD4+ T cells have been reported [31] and it is
also known that melanocytes can present peptides in an
MHC class II restricted manner [28]. These observations
suggest that melanocyte destruction may not only depend
on MHC class I-restricted cells.
Immunotherapy-associated vitiligo and prognosis
Our case series is too limited to aVord decisive conclusions
on the prognostic value of vitiligo on melanoma disease.
The presence of durable non-progressive disease in patients
2 and 3 suggest that the immunotherapy induced vitiligo
lesions are a favourable prognostic factor. We further show
Fig. 2 Vitiligo inWltrating lymphocytes produce IFN- and IL-2 upon
speciWc stimulation. IFN- (black bars) and IL-2 (white bars) produc-
tion of VILs after stimulation with non-speciWc and speciWc stimuli of
patient 1 (a) patient 2 (b) and patient 3 (c). T2 cells are loaded with
respectively irrelevant peptide, tyrosinase peptide and gp100 peptides.
BLM cells are transfected with respectively control protein G250,
tyrosinase protein and gp100 protein (see also material en methods).
From patients 1 and 2 we cultured melanoma cell lines, the VILs pro-
duced high levels of IFN- and IL-2 when stimulated by the autologous




















































































































150 Cancer Immunol Immunother (2009) 58:145–151that all three patients have a relatively high number of
MDA-speciWc T cells in the blood, DTH biopsies and mela-
noma. Earlier papers have described a correlation with the
presence of MDA-speciWc T cells in these compartments
and favourable outcome [2, 5].
Despite the presence of functional melanoma speciWc T
cells, patient 1 had progressive disease. This is intriguing
since the tumor expressed the MDAs gp100 and Melan-A
(IHC, Fig. 3a, b) and was inWltrated by CTLs that speciW-
cally recognize these epitopes (inserts Fig. 3a, b; Table 1).
Several mechanisms may account for the escape of mela-
noma cells to immune surveillance [21]. It has recently
been published that CD4+FoxP3+CD25+ regulatory T cells
(Tregs) can inWltrate melanoma tumors and locally sup-
press cytotoxic anti-tumor responses, also in vaccinated
melanoma patients [1]. InWltration of melanoma tumors
with Tregs correlates with poor prognosis [27]. In the mela-
noma metastasis of patient 1, we detected that 27% of the
tumor inWltrating CD4+ T cells consisted of CD4+FoxP3+
CD25+CD127- Tregs vs 4% of Tregs in the blood of this
patient (data not shown).
Altogether, our data support an association between viti-
ligo and favourable outcome. However, active vaccine-
induced vitiligo does not exclude tumor progression. The
dichotomy between MDA-speciWc CTL responses in mela-
noma and vitiligo might result from quantitative CTL
diVerences, the quality of the CTLs such as T cell receptor
aYnity and cytokine production [20], the amount of antigen
presented [8, 23] and the diVerent environmental conditions
in which these T cells exert their function [21].
Concluding remarks
Melanoma-associated vitiligo is more often seen in patients
who undergo immunotherapy. We demonstrate that immu-
notherapy against gp100 and tyrosinase antigens can induce
speciWc and functional CTLs that invade both melanoma
and vitiligo lesions. This directly links the occurrence of
vitiligo to the immuno-therapeutic intervention.
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